NCT04561492Active, not recruitingPhase 2
Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma
Exploratory Study Evaluating the Relevance of [68Ga]Ga -PentixaFor for Initial Staging and Therapeutic Evaluation of Symptomatic Multiple Myeloma Patients in First Line Treatment or in Relapse
Source: ClinicalTrials.gov · Last updated 5 Oct 2026
Brief summary (registry, in English)
The aim of our study is to confirm the relevance of PET using \[68Ga\]Ga -PentixaFor ligand, in comparison with FDG, for initial staging and therapeutic evaluation of symptomatic multiple myeloma patients in first line treatment or in relapse. The prognostic value of positive CXCR4 expression will also be assessed and \[68Ga\]Ga -PentixaFor/FDG discordances explored.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- First submitted
- 3 Sept 2020
- Start date
- 21 Sept 2021
- Primary completion date
- 21 Dec 2029
- Lead sponsor
- Nantes University Hospital
- Diseases
- Multiple myeloma
- NCT number
- NCT04561492
- EU CT number
- 2024-516752-18-00
- EudraCT number
- 2020-004268-24
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 45
- From 21 Sept 2021 to the primary completion date, 21 Dec 2029
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous or concurrent second malignancy except for adequately treated basal cell carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively treated solid cancer, with no evidence of disease for at least 2 years
Other illness
- HIV positive, active Hepatitis B or C
- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
- Known active infection
- Patient with uncontrolled insulin-dependent or non-insulin-dependent diabetes mellitus
Lab values
- eGFR \< 50 ml/min by MDRD or CKDEPI
Other
- Childbearing or child breast feeding women
- Women or men without effective contraceptive barrier if needed
- Patient under guardianship or trusteeship
- Patient under judicial protection
Who the study is looking for
- Age ≥ 18 years
- Symptomatic MM patients according to IMWG criteria (12) requiring first-line treatment
- Written and signed informed consent (obtained on the screening day at the latest and before any investigation)
- ECOG (Eastern Cooperative Oncology Group) \< 2
- Patient affiliated to or beneficiary of the National Health Service
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hopital Huriez Coordinator of this site? Confirm its status | Lille Cedex | France | Active, not recruiting |
| Centre Hospitalier Universitaire De Nantes Coordinator of this site? Confirm its status | Nantes Cedex 1 | France | Active, not recruiting |
| Hopital Tenon Coordinator of this site? Confirm its status | Paris Cedex 20 | France | Active, not recruiting |
| Centre Hospitalier Universitaire de Bordeaux Coordinator of this site? Confirm its status | Pessac | France | Active, not recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.